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Preoperative platelet-lymphocyte ratio is
superior to neutrophil-lymphocyte ratio as
a prognostic factor for soft-tissue sarcoma
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Abstract
Background: Inflammation can promote tumor growth, invasion, angiogenesis and even metastasis. Inflammatory
markers have been identified as prognostic indicators in various malignances. This study compared the usefulness
of platelet-lymphocyte ratio (PLR) with that of neutrophil-lymphocyte ratio (NLR) for predicting outcomes of
patients who underwent radical resection for soft tissue sarcoma (STS).
Methods: We included 222 STS patients in this retrospective study. Kaplan-Meier curves and multivariate Cox
proportional models were used to calculate overall survival (OS) and disease free survival (DFS).
Results: In univariate analysis, elevated PLR and NLR were both significantly associated with decreased OS. In
multivariate analysis, PLR (HR: 2.60; 95 % CI: 1.17–5.74, P = 0.019) but not NLR was still identified as independent
predictors of outcome. Median OS was 62 and 76 months for the high PLR and low PLR groups, respectively.
High PLR and NLR were both significantly associated with shorter DFS in univariate analysis, with median DFS of
18 and 57 months in the high PLR and low PLR groups. In multivariate analysis, elevated PLR (HR: 1.77; 95 % CI:
1.05–2.97, P = 0.032) was also related to decreased DFS.
Discussion: Our findings provide a new and valuable clue for diagnosing and monitoring STS. Prediction of disease
progression is not only determined by the use of clinical or histopathological factors including tumor grade, tumor
size, and tumor site but also by host-response factors such as performance status, weight loss, and systemic
inflammatory response. They also significantly affect clinical outcomes. Thus, PLR can be used to enhance clinical
prognostication. Furthermore, the PLR can be assessed from peripheral blood tests that are routinely available without
any other complicated expenditure, thus providing lower cost and greater convenience for the prognostication.
Conclusion: Elevated preoperative PLR as an independent prognostic factor is superior to NLR in predicting clinical
outcome in patients with STS.
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Background
Soft tissue sarcomas (STSs) account for less than 1 % of
all cancers [1]. Primary treatments for STS include surgi-
cal resection with or without adjuvant radiation; however,
the 5-year probability of local recurrence and metastasis
remains high [2–4].
The prognosis of STS depends on clinical and histo-
logic characteristics. Established prognostic and predict-
ive factors are age at diagnosis, tumor size, tumor site,
histologic grade, histologic subtype, tumor depth and
margin status [5].
Several molecular biomarkers have also been associated
with outcome in STS. For example, methylated RASSF1A
was significantly related with the risk of death for STS
patients [6]; high serum osteopontin is correlated with
poor prognosis in STS [7]; Brownhill et al. have advocated
use of the proliferation index (by detecting Ki-67) in a risk
model of outcome for Ewing’s sarcoma [8]. However, this
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method is still under investigation and its clinical applica-
tions are limited by high costs.
The neoplasm microenvironment, as measured by a var-
iety of blood parameters, significantly contributes to the de-
velopment and progression of malignancies. For example,
C-reactive protein, a non-specific blood biomarker of
acute-phase inflammatory response, is often elevated in dif-
ferent cancer types [9–13]. Raised platelet counts predicts
inferior survival in ovarian cancer, lung cancer, colon can-
cer, pancreatic cancer, and is potentially associated with
mechanisms (such as increased thrombogenicity) that affect
angiogenesis [14–17]. Additionally, patients with high neu-
trophil density reportedly have worse outcomes compared
with those with low neutrophil density [18], whereas pa-
tients with high lymphocyte density apparently have better
outcomes than those with low levels [19]. As NLR and PLR
can be regarded as two representative indexes of systemic
inflammation, we have used them to predict clinical out-
come in patients with STSs.
To date, PLR has been identified as a reliable and easily
accessible prognostic factor in ovarian cancer [20], colo-
rectal cancer [21], breast cancer [22] and non-small-cell
lung cancer [23]. NLR has also been shown to have prog-
nostic value in various cancers [24, 25]. A meta-analysis of
the prognostic value of blood NLR on clinical outcome in
solid tumors showed that high NLR was associated with
shorter survival [26]. Nevertheless, insufficient data exists
for PLR versus NLR in STS. The aim of our study was to
evaluate the effects of preoperative PLR and NLR on OS,
and DFS in patients with soft-tissue sarcoma.
Methods
Subjects
We included 222 STS patients who underwent extensive
and radical resection at the Sun Yat-sen University Cancer
Center in Guangzhou, China, between 2000 and 2010 in
this retrospective study. Written informed consent was
obtained from each patient. Ethical approval was given by
the medical ethics committee of Sun Yat-sen University
Cancer Center IRB (reference number: B2014-03-20). All
patients had confirmed STS, and none had received
chemotherapy before collection of the blood count data.
Patients were excluded if they presented with active
infections, hematological disorders or malignancies, or
autoimmune disorders, or if they were on steroids.
Preoperative blood cell counts were obtained within
7 days before surgery by Sysmex XE-5000™ Automated
Hematology System (Shanghai, China). Data, including
clinical and histopathological parameters, were collected
through database chart review. Disease staging was
classified according to the American Joint Committee
on Cancer (AJCC)7th Edition [27] and tumors were
graded according to the French Federation of Cancer
Centers Sarcoma Group grading system [28]. Adjuvant
chemotherapy was administered in 39 patients (17.6 %),
and adjuvant radiotherapy treatment in 65 patients
(29.3 %). Doxorubicin-based combination chemotherapy
regimens were mostly used in patients with postoperative
chemotherapy. Patients with stage IV disease and a single
resectable metastasis qualified for surgery; postoperative
RT was administered to improve local control for
patients with high-grade STS or positive surgical
margins. Follow-up examinations were provided by
the independent follow-up program department in Sun
Yat-sen University at regular intervals (every 3 months in
years 1–3, 6 months in years 4–5, and 12 months in years
6–15 after diagnosis).
Statistical analysis
The primary end point of the study was OS, which was
defined as the time from radical surgery to the date of
death. The secondary end point of the study was DFS,
which was calculated from the date of curative resection
to the date of the tumor recurrence or distant metasta-
sis. The DFS was censored at the time of death or at the
last follow-up if the patient had remained disease-free by
that time. Optimal cutoff values for the PLR and NLR
were calculated by applying receiver operating curve
(ROC) analysis. PLR was calculated as the absolute
platelet count measured in × 109/L, divided by the abso-
lute lymphocyte count measured in × 109/L. The NLR
was calculated as the absolute neutrophil count mea-
sured in × 109/L, divided by the absolute lymphocyte
count measured in × 109/L.
Associations between clinical and histopathological pa-
rameters with OS and DFS were analyzed using Kaplan-
Table 1 Histologic type
Number Percent
Undifferentiated pleomorphic sarcoma/MFH 59 26.6
Fibrosarcoma 20 9.0
Dermatofibrosarcoma proberans 28 12.6
Well-differentiated liposarcoma 13 5.9
Myxoid liposarcoma 12 5.4
Pleomorphic liposarcoma 5 2.3
Leiomyosarcoma 13 5.9
Rhabdomyosarcoma 10 4.5
Synovial sarcoma 28 12.6
Epithelioid sarcoma 1 0.5
Angiosarcoma 8 3.6
Alveolar soft part sarcoma 5 2.3
MPNST 10 4.5
PNET 6 2.7
Malignant Triton Tumor 1 0.5
Mesenchymal chondrosarcoma 3 1.4
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Table 2 Clinical-pathological characteristics of soft tissue sarcoma patient
Overall population N (%) PLR NLR
<133.915 ≥133.915 P <2.5 ≥2.5 P
N = 146 N = 76 N = 160 N = 62
Age at operation(years) 0.091 0.067
<65 205(92.3) 138(94.5) 67(88.2) 151(94.4) 54(87.1)
≥65 17(7.7) 8(5.5) 9(11.8) 9(5.6) 8(12.9)
Gender 0.02 0.206
Female 96(43.2) 55(37.7) 41(53.9) 65(40.6) 31(50.0)
Male 126(56.8) 91(62.3) 35(46.1) 95(59.4) 31(50.0)
Performance status 0.002 <0.001
0 ~ 1 173(77.9) 123(84.2) 50(65.8) 137(85.6) 35(58.1)
≥2 49(22.1) 23(15.8) 26(34.2) 23(14.4) 26(41.9)
Diabetes mellitus 0.013 0.067
Yes 4(1.8) 0(0) 4(5.3) 1(0.6) 3(4.8)
No 218(98.2) 146(100.0) 72(94.7) 159(99.4) 59(95.2)
Cardiopulmonary disease 1.000 1.000
Yes 12(5.4) 8(5.5) 4(5.3) 9(5.6) 3(4.8)
No 210(94.6) 138(94.5) 72(94.7) 151(94.4) 59(95.2)
Ever smoked 0.003 0.300
Yes 34(15.3) 30(20.5) 4(5.3) 27(16.9) 7(11.3)
No 188(84.7) 116(79.5) 72(94.7) 133(83.1) 55(88.7)
Tumor depth 0.024 0.001
Superficial 87(39.2) 65(44.5) 22(28.9) 74(46.3) 13(21.0)
Deep 135(60.8) 81(55.5) 54(71.1) 86(53.8) 49(79.0)
Tumor grade 0.028 0.047
G1 65(29.3) 50(34.2) 15(19.7) 55(34.4) 10(16.1)
G2 99(44.6) 65(44.5) 34(44.7) 67(41.9) 32(51.6)
G3 36(16.2) 17(11.6) 19(25.0) 23(14.4) 13(21.0)
Unknown 22(9.9) 14(9.6) 8(10.5) 15(9.4) 7(11.3)
Tumor size 0.005 <0.001
<5 cm 105(47.3) 79(54.1) 26(34.2) 88(55.0) 17(27.4)
≥5 cm 117(52.7) 67(45.9) 50(65.8) 72(45.0) 45(72.6)
Tumor site 0.282 0.002
Upper extremity 21(9.5) 11(7.5) 10(13.2) 18(11.3) 3(4.8)
Lower extremity 60(27.0) 41(28.1) 19(25.0) 46(28.8) 14(22.6)
Thoracic/trunk 77(34.7) 54(37.0) 23(30.3) 62(38.8) 15(24.2)
Intra-abdomina 35(15.8) 19(13.0) 16(21.1) 17(10.6) 18(29.0)
Head-neck 29(13.1) 21(14.4) 8(10.5) 17(10.6) 12(19.4)
AJCC stage 0.056 0.002
IA + IB 68(30.6) 52(35.6) 16(21.1) 57(35.6) 11(17.7)
IIA + IIB 107(48.2) 68(46.6) 9(51.3) 77(48.1) 30(48.4)
III + IV 34(15.3) 17(11.6) 17(22.4) 16(10.0) 18(29.0)
Unknown 13(5.9) 9(6.2) 4(5.3) 10(6.3) 3(4.8)
Bold print indicates statistical significance
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Table 3 Univariate and multivariate Cox proportional analysis regarding overall survival
Univariate analysis Multivariate analysis
Parameter HR (95 % CI) P-value HR (95 % CI) P-value
Age at operation(years)
<65 1 (referent) 0.220 1 (referent) 0.219
≥65 1.70(0.73-4.00) 2.06(0.65-6.49)
Gender
Female 1 (referent) 0.772 1 (referent) 0.615
Male 1.09(0.62-1.89) 1.20(0.59-2.45)
Performance status
0 ~ 1 1 (referent) 0.006 1 (referent) 0.975
≥2 2.22 (1.26-3.93) 0.99 (0.48-2.03)
Diabetes mellitus
No 1 (referent) 0.943 1 (referent) 0.218
Yes 1.07(0.15-7.78) 0.27(0.03-2.18)
Cardiopulmonary disease
No 1 (referent) 0.344 1 (referent) 0.342
Yes 0.38(0.06-2.78) 0.33(0.03-3.27)
Ever smoked
No 1 (referent) 0.579 1 (referent) 0.273
Yes 1.23(0.60-2.52) 1.69 (0.66-4.32)
Tumor depth
Superficial 1 (referent) <0.001 1 (referent) 0.096
Deep 6.09 (2.74-13.53) 2.41(0.85-6.77)
Tumor grade




<5 cm 1 (referent) 0.001 NA NA
≥5 cm 2.87(1.55-5.32)
Tumor site
Trunk&extremity 1 (referent) <0.001 1 (referent) 0.002
head/neck&intra-abdominal 4.48(2.57-7.81) 3.14 (1.52-6.48)
AJCC stage
IA + IB 1 (referent) 0.001 1 (referent) 0.002
IIA + IIB 5.13(1.97-13.37) <0.001 3.92 (1.43-10.76) 0.008
III + IV 10.56 (3.71-30.08) 7.45(2.44-22.81)
Adjuvant radiotherapy
Yes 1 (referent) 0.798 1 (referent) 0.692
No 1.08 (0.60-1.95) 0.86(0.40-1.84)
Adjuvant chemocherapy
Yes 1 (referent) 0.320 1 (referent) 0.929
No 1.44 (0.70-2.97) 1.04(0.45-2.41)
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Meier curves and compared by the log-rank test. The
chi-square (Χ2) test was used to analyze the relationship
between PLR or NLR and clinicopathological parame-
ters. Univariate and multivariate Cox-regression analyses
were performed to determine effects of probable prog-
nostic factors, including age, gender, performance status,
diabetes mellitus, cardiopulmonary disease, smoking his-
tory, tumor depth, tumor site, tumor size, grade, adju-
vant radiotherapy, adjuvant chemotherapy and AJCC
stage on OS and DFS. Hazard ratios (HRs) estimated
from the Cox analysis were reported as relative risks
with corresponding 95 % confidence intervals(CIs). All
analyses were performed using the SPSS statistical soft-
ware package (SPSS statistics 17.0). P < 0.05 was consid-
ered as statistically significant.
Results
Patient characteristics and histologic subtype
The median age of the 222 patients with histologically
confirmed STS who were included in the present study
at surgery was 37 years (range, 5–78 years), and their
median follow-up time was 74 months (range, 1–176
months [censored]). Patients were classified into differ-
ent subtypes as shown in Table 1.
Patients’ mean blood values were as follows: platelet
count: 252.02 ± 94.752; neutrophil count: 4.468 ± 2.543;
lymphocyte count: 2.151 ± 0.707; PLR: 132.069 ± 80.600;
and NLR: 2.407 ± 2.395. We used ROC analysis criteria
to determine the optimal cutoffs as 133.915 (AUC:
0.640, 95 % CI: 0.541–0.739, P = 0.005), and 2.5 (AUC:
0.632, 95 % CI: 0.533–0.731, P = 0.009) for PLR and
NLR, respectively.
Relationships between PLR or NLR and other clinical
characteristics
Elevated PLR was significantly associated with female
sex, poor performance status, diabetes mellitus, smoking
history, deep tumor depth, high tumor grade and large
tumor size; Elevated NLR was significantly associated
with poor performance status, deep tumor depth, high
tumor grade, large tumor size, deep tumor site and high
AJCC stage (Table 2).
Prognostic significance of the clinical characteristics in STS
In univariate analysis, we found significant associations
of performance status, tumor depth, tumor grade, tumor
size, tumor site, AJCC stage, PLR and NLR with OS and
DFS. In multivariate analysis, we observed significant as-
sociations of tumor site, AJCC stage and PLR, but not
NLR with OS (Table 3). And significant associations
remained among tumor depth, AJCC stage and PLR
with DFS (Table 4). Multivariate analyses were per-
formed based on age at surgery, gender, performance
status, diabetes mellitus, cardiopulmonary disease, smok-
ing history, tumor depth, tumor site, AJCC stage, adjuvant
radiotherapy, adjuvant chemotherapy, PLR and NLR. The
reason why factors such as tumor grade and tumor size
were excluded is to eliminate the influence of statistical
collinearity. Another multivariate analysis model including
tumor grade and tumor size is available (Additional file 1:
Table S1 and Additional file 2: Table S2).
Prognostic significance of PLR and NLR in STS
In univariate analysis, shorter OS was significantly asso-
ciated with both high PLR (HR: 2.49; 95 % CI: 1.41–4.39;
P = 0.002; Table 3; Fig. 1) and high NLR (HR: 2.83; 95 %
CI: 1.61–4.99; P < 0.001; Table 3). In multivariate ana-
lysis, tumor site, AJCC stage, and PLR (HR: 2.60; 95 %
CI: 1.17–5.74, P = 0.019) were still identified as inde-
pendent prognostic factors (Table 3; Additional file 3:
Table S3), but NLR was not (Table 3; Additional file 4:
Table S4). Patients with high PLR had a median OS of
62 months, whereas those with low PLR had a median
OS of 76 months. In univariate analyses, shorter DFS
was associated with both high PLR (HR: 1.75; 95 % CI:
1.14–2.70, P = 0.011; Table 4; Fig. 2) and high NLR (HR:
1.71; 95 % CI: 1.10–2.66, P = 0.018; Table 4). However,
elevated PLR (HR: 1.77; 95 % CI: 1.05–2.97, P = 0.032)
but not NLR was independently associated with de-
creased DFS in multivariate analysis (Table 4). Patients
with high PLR had a median DFS of 18 months, and
those with low PLR had a median DFS of 57 months.
Prognostic significance of PLR in different histologic
types of STS
In subgroup analyses of the four major histologic types
(undifferentiated [spindle cell and pleomorphic] sarcoma,
Table 3 Univariate and multivariate Cox proportional analysis regarding overall survival (Continued)
PLR
<133.915z 1 (referent) 0.002 1 (referent) 0.019
≥133.915 2.49 (1.41-4.39) 2.60(1.17-5.74)
NLR
<2.5 1 (referent) <0.001 1 (referent) 0.881
≥2.5 2.83 (1.61-4.99) 1.06(0.52-2.16)
Bold print indicates statistical significance
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Table 4 Univariate and multivariate Cox proportional analysis regarding disease-free-survival
Univariate analysis Multivariate analysis
Parameter HR (95 % CI) P-value HR (95 % CI) P-value
Age at operation(years)
<65 1 (referent) 0.362 1 (referent) 0.370
≥65 1.47 (0.64-3.37) 1.69(0.54-5.31)
Gender
Female 1 (referent) 0.436 1 (referent) 0.643
Male 0.85(0.56-1.29) 0.89(0.54-1.46)
Performance status
0 ~ 1 1 (referent) 0.001 1 (referent) 0.596
≥2 1.81(1.15-2.85) 1.16(0.68-1.97)
Diabetes mellitus
No 1 (referent) 0.02 1 (referent) 0.575
Yes 5.51(1.31-23.09) 0.66(0.16-2.78)
Cardiopulmonary disease
No 1 (referent) 0.510 1 (referent) 0.247
Yes 0.68(0.21-2.15) 2.52(0.53-12.06)
Ever smoked
No 1 (referent) 0.470 1 (referent) 0.064
Yes 1.23 (0.70-2.19) 1.95(0.96-3.96)
Tumor depth
Superficial 1 (referent) <0.001 1 (referent) 0.002
Deep 4.07 (2.39-6.93) 2.841.47-5.49)
Tumor grade
G1 1 (referent) 0.003 NA NA
G2 2.54 (1.37-4.71) <0.001
G3 6.71(3.43-13.12)
Tumor size
<5 cm 1 (referent) <0.001 NA NA
≥5 cm 2.22(1.43-3.45)
Tumor site
Trunk&extremity 1 (referent) <0.001 1 (referent) 0.132
head/neck&intra-abdominal 2.26 (1.48-3.46) 1.49(0.89-2.52)
AJCC stage
IA + IB 1 (referent) 0.001 1 (referent) 0.002
IIA + IIB 2.72(1.51-4.89) <0.001 1.85(0.98-3.50) 0.057
III + IV 5.37(2.72-10.61) 3.60(1.74-7.46)
Adjuvant radiotherapy
Yes 1 (referent) 0.216 1 (referent) 0.560
No 1.31(0.85-2.03) 1.17(0.70-1.95)
Adjuvant chemocherapy
Yes 1 (referent) 0.316 1 (referent) 0.753
No 1.30(0.78-2.19) 1.10(0.61-1.97)
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fibrosarcoma, liposarcoma, and leiomyosarcoma), high
PLR was associated with shorter OS in undifferentiated
sarcoma in univariate analysis (HR: 3.50; 95 % CI: 1.21–
10.11; P = 0.021; Table 5) and remained significant in
multivariate analysis (HR: 3.91; 95 % CI: 1.02–14.99; P =
0.047; Table 5).
Discussion
Our present study showed that high preoperative PLR is
independently associated with survival in patients who
underwent extensive radical surgery.
Accumulating evidence has shown that platelets can
support various steps of cancer development and tumor
progression by promoting cancer cell proliferation, tumor
angiogenesis and metastasis. In addition to their function
in hemostasis, platelets are also involved in inflammatory
disease and cancer [29]. Platelets reportedly have a stimu-
latory effect on ovarian cancer cell proliferation via the
transforming growth factor (TGF)-β [30]. They have also
been shown in vitro to inhibit apoptosis and reverse
cell-cycle arrest induced by chemotherapeutic agents
(such as 5-fluorouracil and paclitaxel) and enhance
DNA repair in cancer cells [31]. Secondly, as tumor
growth seems to depend on the formation of new blood
vessels [32], platelets, which carry a variety of proangio-
genic factors, affect regulation of cancer angiogenesis.
Interestingly, cancer cells were also suggested to induce
release of vascular endothelial growth factor from
Table 4 Univariate and multivariate Cox proportional analysis regarding disease-free-survival (Continued)
PLR
<133.915 1 (referent) 0.011 1 (referent) 0.032
≥133.915 1.75(1.14-2.70) 1.77(1.05-2.97)
NLR
<2.5 1 (referent) 0.018 1 (referent) 0.516
≥2.5 1.71(1.10-2.66) 0.83(0.48-1.44)
Bold print indicates statistical significance
Fig. 1 Kaplan-Meier curves for overall survival of patients with soft tissue sarcoma by low vs high platelet-lymphocyte ratio. PLR≥ 133.915 is associated
with poor survival (P = 0.001)
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platelets, resulting in angiogenesis [33]. Platelets have
been linked to tumor metastasis [34, 35] with under-
lying mechanisms that include attenuating the ability
of natural killer cells to shield circulating cancer cells
against the immune system [36] and inducing epithelial–
mesenchymal transition [37].
As with platelets, lymphocytes are a significant blood
parameter related to immune surveillance. Thus, high
lymphocytic infiltrate is associated with improved sur-
vival and superior response to systemic therapy [38, 39]
whereas a low peripheral blood lymphocyte counts are
related to poor cancer prognoses [40, 41].
Fig. 2 Kaplan-Meier curves for disease-free survival of patients with soft tissue sarcoma by low vs high platelet-lymphocyte ratio. PLR ≥ 133.915 is
associated with poor survival (P = 0.01)
Table 5 Association of prognostic factors and PLR with overall survival in specific histologic tumor types
Univariate analysis Multivariate analysis
Parameter HR (95 % CI) P-value HR (95 % CI) P-value
Undifferentiated(spindle cell and pleomorphic) sarcoma
1 (referent) 0.021 1 (referent) 0.047
3.50(1.21-10.11) 3.91(1.02-14.99)
Fibrosarcoma
1 (referent) 0.160 1 (referent) 0.157
2.81(0.67-11.81) 3.16(0.64-15.59)
Liposarcoma
1 (referent) 0.177 1 (referent) NA
5.22(0.47-57.67) NA
Leiomyosarcoma
1 (referent) 0.425 1 (referent) NA
2.08(0.34-12.62) NA
Bold print indicates statistical significance
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A combined index of platelet and lymphocyte counts
has been investigated as prognostic factor for some can-
cers. Recently, a meta-analysis, comprising 12,754 patients,
of the association of blood PLR and overall survival in
solid tumors concluded that high PLR was independently
associated with shorter OS in various solid tumors [42].
Asher et al. reported that high preoperative PLR was asso-
ciated with poor survival in ovarian cancer [20]; and
Krenn-Pilko et al. found that preoperative PLR as an inde-
pendent prognostic marker for survival in breast cancer
patients [22]. Szkandera et al. evaluated the prognostic sig-
nificance of PLR in STS patients and found statistically sig-
nificant associations in univariate, but not multivariate
analyses, and that high preoperative NLR was an inde-
pendent prognostic factor in multivariate analysis [43, 44],
which differed from our results. However, their studies
used different cancer populations, different NLR and PLR
cut-off values, and patient cohorts of a different median
age from our study, which might hinder the comparability
of their results with ours. Moreover, these inflammatory
factors may be affected by potential confounding fac-
tors, including smoking history, performance status
and co-morbidities. Thus, the significance of inflammatory
markers in STS requires further evaluation.
Findings that PLR is superior to NLR in predicting
clinical outcomes vary in different studies that address
different cancers. Our findings are consistent with some
prior studies [20, 45], but not others [46, 47]. As we have
mentioned, differences in race [48] or cutoff values may
affect the results. Racial variations are known to affect
cutoff values. For example, Caucasians have higher per-
ipheral blood neutrophil counts and lower lymphocyte
counts than do Asians [49]; NLR ≥ 5 was considered
high in reports on Caucasian patients [50–52], whereas
some studies on Asian patients used NLR >3 and >4 as
cutoff points [53, 54]. For PLR, some reports used 150
or 300 as cutoff points [21, 53], some studies identified
the ideal cutoff value by applying ROC curve and the
cutoff points [22, 23].
Our findings provide a new and valuable clue for diag-
nosing and monitoring STS. Prediction of disease pro-
gression is not only determined by the use of clinical or
histopathological factors including tumor grade, tumor
size, and tumor site but also by host-response factors
[55], such as performance status, weight loss, and sys-
temic inflammatory response [56]. They also signifi-
cantly affect clinical outcomes [57]. Thus, PLR can be
used to enhance clinical prognostication. Furthermore,
the PLR can be assessed from peripheral blood tests that
are routinely available without any other complicated ex-
penditure, thus providing lower cost and greater con-
venience for the prognostication.
Nevertheless, this study has some limitations, namely its
retrospective research design. The unavailability of data
regarding cancer-specific survival is another limitation.
Choi et al. assessed multiple preoperative systemic inflam-
matory serum markers and predicted an association be-
tween high inflammatory status and shorter disease-
specific survival in STS [58]. They showed that inflamma-
tory marker values were significantly associated with
histologic grade. Furthermore, the presence of multiple el-
evated markers was the most significant predictor of
disease-specific survival. As NLR may vary by race [59],
the fact that > 95 % of our patients were Asians is another
limitation. Additionally, thrombocytosis and lymphocyto-
penia could have other causes, including bacterial infec-
tions, connective tissue disorders, intense physical
exercise, severe stress. Nevertheless, the association of
poor clinical outcome with high PLR in our results has
not been challenged, considering these limitations.
Conclusion
Our study indicates that PLR is an independent prog-
nostic factor for survival of STS. Validation studies or
large-scale prospective studies are warranted to verify
our findings.
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